Lauren R Pacek1, Andrea H Weinberger2,3, Jiaqi Zhu4, Renee D Goodwin4,5,6. 1. Department of Psychiatry and Behavioral Sciences, Duke School of Medicine, Durham, NC, USA. 2. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. 4. Institute for Implementation Science in Population Health, The City University of New York, New York, NY, US. 5. Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA. 6. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Abstract
AIMS: To estimate trends in the prevalence of cannabis use and risk perceptions of cannabis use from 2005 to 2017 among United States people with and without depression. DESIGN: Linear time trends of the prevalence of any, daily and non-daily past 30-day cannabis use and perceived great risk associated with regular cannabis use (outcome variables) among people with and without past-year depression were assessed using logistic regression with survey year as the predictor. All analyses were adjusted for gender, age, race/ethnicity and income; models assessing time trends of cannabis use prevalence were also adjusted for perceived risk. SETTING: The United States: National Survey on Drug Use and Health, an annual cross-sectional survey, 2005-17 public use data files. PARTICIPANTS: A total of 728 691 people aged ≥ 12 years. MEASUREMENTS: Self-report of any, daily and non-daily past 30-day cannabis use and perceived great risk associated with regular cannabis use. FINDINGS: The prevalence of any, daily and non-daily cannabis use in the past month was higher among those with depression versus those without [e.g. 2017 for any use: 18.94 versus 8.67%; adjusted odds ratio (aOR) = 2.17 (95% confidence interval (CI) = 1.92, 2.45)]. Any, daily and non-daily cannabis use increased among people with and without depression from 2005 to 2017, yet the increase in any (aORs = 1.06 versus 1.05; P = 0.008) and daily (aORs = 1.10 versus 1.07; P = 0.021) cannabis use adjusted for socio-demographic characteristics was more rapid among those with depression. Perception of great risk associated with regular cannabis use was significantly lower among those with depression (P < 0.001) and decreased significantly more rapidly over the study period among people with depression, compared with those without (aORs = 0.89 versus 0.92; P < 0.001). CONCLUSIONS: The prevalence of cannabis use in the United States increased from 2005 to 2017 among people with and without depression and was approximately twice as common among those with depression. People with depression experienced a more rapid decrease in perception of risk, which may be related to the more rapid increase in any and daily past-month cannabis use in this group.
AIMS: To estimate trends in the prevalence of cannabis use and risk perceptions of cannabis use from 2005 to 2017 among United States people with and without depression. DESIGN: Linear time trends of the prevalence of any, daily and non-daily past 30-day cannabis use and perceived great risk associated with regular cannabis use (outcome variables) among people with and without past-year depression were assessed using logistic regression with survey year as the predictor. All analyses were adjusted for gender, age, race/ethnicity and income; models assessing time trends of cannabis use prevalence were also adjusted for perceived risk. SETTING: The United States: National Survey on Drug Use and Health, an annual cross-sectional survey, 2005-17 public use data files. PARTICIPANTS: A total of 728 691 people aged ≥ 12 years. MEASUREMENTS: Self-report of any, daily and non-daily past 30-day cannabis use and perceived great risk associated with regular cannabis use. FINDINGS: The prevalence of any, daily and non-daily cannabis use in the past month was higher among those with depression versus those without [e.g. 2017 for any use: 18.94 versus 8.67%; adjusted odds ratio (aOR) = 2.17 (95% confidence interval (CI) = 1.92, 2.45)]. Any, daily and non-daily cannabis use increased among people with and without depression from 2005 to 2017, yet the increase in any (aORs = 1.06 versus 1.05; P = 0.008) and daily (aORs = 1.10 versus 1.07; P = 0.021) cannabis use adjusted for socio-demographic characteristics was more rapid among those with depression. Perception of great risk associated with regular cannabis use was significantly lower among those with depression (P < 0.001) and decreased significantly more rapidly over the study period among people with depression, compared with those without (aORs = 0.89 versus 0.92; P < 0.001). CONCLUSIONS: The prevalence of cannabis use in the United States increased from 2005 to 2017 among people with and without depression and was approximately twice as common among those with depression. People with depression experienced a more rapid decrease in perception of risk, which may be related to the more rapid increase in any and daily past-month cannabis use in this group.
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: L John Horwood; David M Fergusson; Carolyn Coffey; George C Patton; Robert Tait; Diana Smart; Primrose Letcher; Edmund Silins; Delyse M Hutchinson Journal: Drug Alcohol Depend Date: 2012-06-29 Impact factor: 4.492
Authors: Edmund Silins; L John Horwood; George C Patton; David M Fergusson; Craig A Olsson; Delyse M Hutchinson; Elizabeth Spry; John W Toumbourou; Louisa Degenhardt; Wendy Swift; Carolyn Coffey; Robert J Tait; Primrose Letcher; Jan Copeland; Richard P Mattick Journal: Lancet Psychiatry Date: 2014-09-10 Impact factor: 27.083
Authors: Katarina Guttmannova; Rick Kosterman; Helene R White; Jennifer A Bailey; Jungeun Olivia Lee; Marina Epstein; Tiffany M Jones; J David Hawkins Journal: Drug Alcohol Depend Date: 2017-07-18 Impact factor: 4.492
Authors: Courtney R Quick; Kevin P Conway; Joel Swendsen; Emma K Stapp; Lihong Cui; Kathleen R Merikangas Journal: JAMA Psychiatry Date: 2022-07-01 Impact factor: 25.911
Authors: Ayeila Z B Daneshmend; Jayme Stewart; Dana A Jarkas; Sabina I Franklyn; Robert L Gabrys; Zachary R Patterson; Alfonso Abizaid; Kim G C Hellemans; Robyn J McQuaid Journal: Int J Environ Res Public Health Date: 2022-07-29 Impact factor: 4.614
Authors: Benjamin H Han; Makaya Funk-White; Roxanne Ko; Tala Al-Rousan; Joseph J Palamar Journal: J Am Geriatr Soc Date: 2021-05-26 Impact factor: 7.538